Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

Key Points

• 4D Molecular Therapeutics has received a "Sell (D-)" rating from Weiss Ratings, signaling concerns about the stock's performance.
• The company's recent earnings report showed a significant miss with a reported EPS of ($0.98), falling short of analysts' expectations.
• 8 analysts have rated the stock as a Buy, while the average target price is set at $30.40, indicating potential upside despite current challenges.

Weiss Ratings reissued their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) in a research note issued to investors on Saturday morning,Weiss Ratings reports.

Several other brokerages also recently issued reports on FDMT. The Goldman Sachs Group cut their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Chardan Capital reissued a "buy" rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th. Barclays lowered their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Finally, Roth Capital lowered their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $30.40.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT traded down $0.02 during trading hours on Friday, hitting $6.16. 342,572 shares of the stock traded hands, compared to its average volume of 978,273. The firm has a 50 day moving average price of $5.15 and a 200 day moving average price of $4.21. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $17.41.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. Equities analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently bought and sold shares of FDMT. Wells Fargo & Company MN boosted its holdings in 4D Molecular Therapeutics by 40.6% in the fourth quarter. Wells Fargo & Company MN now owns 25,852 shares of the company's stock worth $144,000 after purchasing an additional 7,463 shares in the last quarter. Raymond James Financial Inc. bought a new stake in 4D Molecular Therapeutics in the fourth quarter worth $629,000. MetLife Investment Management LLC boosted its holdings in 4D Molecular Therapeutics by 21.7% in the fourth quarter. MetLife Investment Management LLC now owns 35,395 shares of the company's stock worth $197,000 after purchasing an additional 6,312 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in 4D Molecular Therapeutics by 88.3% in the fourth quarter. Hsbc Holdings PLC now owns 34,413 shares of the company's stock worth $190,000 after purchasing an additional 16,142 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in 4D Molecular Therapeutics by 2.3% in the fourth quarter. Northern Trust Corp now owns 440,665 shares of the company's stock worth $2,455,000 after purchasing an additional 9,982 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.